Rehan Verjee Purchases 972 Shares of Tyra Biosciences (NASDAQ:TYRA) Stock

Tyra Biosciences, Inc. (NASDAQ:TYRA) Director Rehan Verjee purchased 972 shares of the stock in a transaction that occurred on Wednesday, September 9th. The stock was bought at an average cost of $20.58 per share, with a total value of $20,003.76. Following the completion of the transaction, the director directly owned 972 shares in the company, valued at $20,003.76. The trade was a ∞ increase in their position. The purchase was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this link.

Tyra Biosciences Price Performance

TYRA opened at $22.03 on Friday. Tyra Biosciences, Inc. has a 1 year low of $11.82 and a 1 year high of $40.65. The company has a market capitalization of $1.31 billion, a price-to-earnings ratio of -9.18 and a beta of 0.73. The firm’s fifty day moving average price is $28.39 and its two-hundred day moving average price is $31.84.

Tyra Biosciences (NASDAQ:TYRA) last announced its earnings results on Tuesday, August 4th. The company reported ($0.69) EPS for the quarter, missing the consensus estimate of ($0.65) by ($0.04). As a group, equities analysts anticipate that Tyra Biosciences, Inc. will post -2.74 EPS for the current year.

Tyra Biosciences News Roundup

Here are the key news stories impacting Tyra Biosciences this week:

• Positive Sentiment: Initial SURF302 results support further development of dabogratinib in bladder cancer, providing evidence of potential activity for Tyra’s lead program. The Pharma Letter article
• Positive Sentiment: Wedbush reaffirmed its “Outperform” rating and maintained a $53 price target, signaling substantial potential upside if the clinical program succeeds. Benzinga analyst rating report
• Positive Sentiment: Director Rehan Verjee purchased 972 shares for approximately $20,004 at an average price of $20.58. The insider purchase may be viewed as a signal of confidence, although its size is modest relative to the company’s market value. SEC insider ownership filing
• Neutral Sentiment: Reported short-interest data showed zero shares sold short and a zero-day short-interest ratio, but the figures appear anomalous and provide little useful information about trading sentiment.
• Negative Sentiment: Coverage indicated that bladder-cancer response rates from SURF302 were below investor expectations, creating uncertainty about dabogratinib’s commercial and regulatory potential. BioSpace article
• Negative Sentiment: HC Wainwright lowered its price target from $45 to $30, although it retained a “Buy” rating, reflecting reduced near-term expectations following the trial update. Benzinga analyst rating report
• Negative Sentiment: Pomerantz LLP announced an investigation into potential claims on behalf of TYRA investors, adding a legal and reputational overhang. The announcement did not establish wrongdoing by Tyra. Pomerantz investor alert

Analyst Ratings Changes

TYRA has been the topic of a number of recent analyst reports. Bank of America lifted their price target on Tyra Biosciences from $37.00 to $42.00 and gave the stock a “buy” rating in a report on Wednesday, June 10th. Cantor Fitzgerald restated an “overweight” rating on shares of Tyra Biosciences in a research note on Thursday. Wolfe Research began coverage on Tyra Biosciences in a research report on Tuesday, May 19th. They set a “peer perform” rating for the company. HC Wainwright lowered their target price on Tyra Biosciences from $45.00 to $30.00 and set a “buy” rating on the stock in a research note on Thursday. Finally, JonesTrading assumed coverage on shares of Tyra Biosciences in a report on Wednesday, June 17th. They issued a “buy” rating and a $56.00 price target on the stock. Eleven analysts have rated the stock with a Buy rating, one has assigned a Hold rating and one has assigned a Sell rating to the company’s stock. Based on data from MarketBeat.com, the company currently has an average rating of “Moderate Buy” and an average target price of $47.88.

Institutional Investors Weigh In On Tyra Biosciences

Hedge funds have recently modified their holdings of the stock. Jupiter Topco LLC bought a new stake in shares of Tyra Biosciences in the second quarter valued at $139,161,000. BlackRock Inc. purchased a new stake in Tyra Biosciences in the 2nd quarter worth about $96,841,000. Commodore Capital LP raised its stake in Tyra Biosciences by 226.3% in the 2nd quarter. Commodore Capital LP now owns 3,100,000 shares of the company’s stock valued at $29,667,000 after acquiring an additional 2,150,000 shares during the period. 5AM Venture Management LLC purchased a new stake in Tyra Biosciences during the second quarter valued at about $32,875,778. Finally, Janus Henderson Group PLC lifted its holdings in Tyra Biosciences by 32.5% during the first quarter. Janus Henderson Group PLC now owns 3,890,589 shares of the company’s stock valued at $148,867,000 after purchasing an additional 955,147 shares during the last quarter. Institutional investors own 84.14% of the company’s stock.

Tyra Biosciences Company Profile

Tyra Biosciences, Inc is a clinical-stage biotechnology company focused on developing precision medicines for diseases with limited treatment options. The company uses its proprietary SNÅP platform to design small-molecule therapies intended to selectively target disease-driving genetic alterations while addressing resistance mechanisms that can reduce the effectiveness of existing treatments.

Tyra’s lead programs are directed at fibroblast growth factor receptor (FGFR) biology. TYRA-300 is an oral, selective FGFR3 inhibitor being developed for conditions including FGFR3-altered urothelial cancer and achondroplasia, a genetic skeletal disorder.